Investors

News Releases

News Releases

REGENXBIO to Present at Upcoming Investor Conferences

November 6, 2018 at 7:00 AM EST

ROCKVILLE, Md., Nov. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following November investor conferences:

Credit Suisse 27th Annual Healthcare Conference

Date: Tuesday, November 13, 2018

Location: The Phoenician Hotel, Scottsdale, AZ

Presentation: Tuesday, November 13, 2018 at 8:35 a.m. MT


Barclays Gene Editing & Gene Therapy Summit

Date: Thursday, November 29, 2018

Location: Barclays, New York, NY

Presentation: Thursday, November 29, 2018 at 11:45 a.m. ET

A live webcast of the Credit Suisse presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following each presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

(PRNewsfoto/REGENXBIO Inc.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-300744177.html

SOURCE REGENXBIO Inc.